After injury, zebrafish can send axons across severed spinal cords and regenerate neural connections. Now, researchers from Duke University have identified a molecule that is important for enabling them to do so. Read More
Apogenix GmbH, of Heidelberg, Germany, said it achieved additional milestones under its deal with Canbridge Life Sciences Ltd., of Beijing, related to the implementation of the technology transfer necessary for the production of the CD95 ligand inhibitor APG101 at the Chinese production site. Read More
Glenmark Pharmaceuticals Ltd., of Mumbai, India, reported preclinical findings suggesting that GBR 1302 is efficient at eliminating tumor cells and has potential for a large therapeutic window. Read More
Omeros Corp., of Seattle, used about $76 million from a new $80 million term loan to repay its obligations under a previous credit facility with less favorable terms. Read More
MELBOURNE, Australia – With the global regenerative medicine market growing at 23 percent annually, Australia is well-positioned to play a significant role in that market, experts said during the AusBiotech conference. Read More
LONDON – Following approval by the European Commission in May, Glaxosmithkline plc's Strimvelis surmounted a critical barrier for gene therapy as a whole, securing reimbursement at €594,000 (US$660,400) per treatment. Read More
SHANGHAI – At the Clinical Trials 9 event last week, it was clear the biopharma industry's optimism has not been dented by the recent CFDA rejection of 1,200 applications – about 70 percent of its workload – for poor quality or fraudulent data. While one would think so many questionable drug applications would cast a pall on the industry, especially among clinical trial experts, that is not exactly the case. Read More
"The average scientist thinks of estrogen as largely mediating gene expression," Eric Prossnitz told BioWorld Today. Estrogen is a steroid hormone, and its classical receptor is a nuclear hormone receptor that acts as a transcription factor once it is activated by estrogen binding. Read More
The failure of a gentamicin-containing collagen sponge called Cogenzia to deliver statistically significant improvements in clinical cure rates for patients with diabetic foot infections during twin phase III studies sunk shares of Innocoll Holdings plc (NASDAQ:INNL) on Friday, driving them 17.4 percent lower to a $2.89 close after touching a 52-week low. Read More
Analysts already were asking Exelixis Inc. about the possibility of "decelerated" growth of Cabometyx (cabozantinib) as the company rolled out third-quarter results that show it doing well with the launch of the tablets, approved in April for advanced renal cell carcinoma patients who have received prior anti-angiogenic therapy. Read More
Signaled by briefing documents posted by the FDA earlier in the week, the efficacy of solithromycin (soli) to treat community-acquired bacterial pneumonia (CABP) was not in dispute even before the agency's Antimicrobial Drugs Advisory Committee (AMDAC) met Friday to discuss new drug applications submitted by sponsor Cempra Inc. for the agent's oral and injectable formulations. Read More
